A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
Titel:
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
Auteur:
Plummer, Ruth Lorigan, Paul Steven, Neil Scott, Lucy Middleton, Mark R. Wilson, Richard H. Mulligan, Evan Curtin, Nicola Wang, Diane Dewji, Raz Abbattista, Antonello Gallo, Jorge Calvert, Hilary